111 Capital’s CorMedix CRMD Stock Holding History

111 Capital’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,671	Closed	-$147K	–	373
2025 Q3	$147K	Buy	+12,671	New	+$153K	0.03%	425

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

111 Capital's CRMD Position: Q4 2025 in Review

111 Capital sold out of CorMedix (CRMD) in Q4 2025, closing a stake of 12,671 shares — an estimated $147K sold.

111 Capital first reported a position in CRMD in Q3 2025 and held it in 1 quarter. The position peaked at $147K in Q3 2025. 198 funds tracked by Wall St. Rank hold CRMD as of Q4 2025.

111 Capital reported no remaining CorMedix position as of Q4 2025 after selling out during the quarter.
111 Capital sold 12,671 CorMedix shares in Q4 2025, an estimated $147K.
111 Capital first reported a position in CorMedix in Q3 2025 and held it in 1 quarter.
111 Capital's CorMedix position peaked at $147K in Q3 2025.
198 funds tracked by Wall St. Rank held CorMedix as of Q4 2025.

Based on 111 Capital's 13F filing for Q4 2025, filed 11 Feb 2026.